NCT03464734View on ClinicalTrials.gov

Pembrolizumab and Nab Paclitaxel in Patients With Metastatic Urothelial Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

January 16, 2019

Primary Completion Date

January 21, 2020

Study Completion Date

January 21, 2020

Conditions
Metastatic Urothelial Carcinoma
Interventions
DRUG

Pembrolizumab and Nanoparticle Albumin-bound Paclitaxel

At study entry, patients will receive 2 cycles of pembrolizumab at the dose of 200 mg, intravenously in 30 min, on day 1 and nab-paclitaxel 125 mg/m2 intravenously in 30-40 min, on day 1 and 8.

Trial Locations (2)

20133

Clinical Trial Center, Istituto Nazionale dei Tumori di Milano, Milan

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

All Listed Sponsors
lead

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

OTHER

NCT03464734 - Pembrolizumab and Nab Paclitaxel in Patients With Metastatic Urothelial Carcinoma | Biotech Hunter | Biotech Hunter